The Centers for Medicare & Medicaid Services Dec. 29 formally rescinded its Most Favored Nation model for Part B drugs. The model was established via interim final rule during the Trump administration to initiate a seven-year, nationwide, mandatory effort to test an alternative way for Medicare to pay for certain Medicare Part B single-source drugs and biologicals. CMS in August signaled its intent to end the model, for which AHA voiced support in an Oct. 11 letter to the agency by arguing that the rule’s “legal infirmities fell within three major categories: (1) failure to follow proper procedures in promulgating the rule, (2) exceeding statutory authority, and (3) constitutional violations.”

Related News Articles

Headline
The Consumer Price Index has climbed 8.6% over the past 12 months before seasonal adjustment, the fastest increase in over 40 years, the Bureau of Labor…
Headline
Launch prices for new brand-name prescription drugs increased 20% per year between 2008 and 2021, according to a study reported yesterday in JAMA. Median…
Headline
In a statement submitted to the Senate Finance Committee for a hearing yesterday on lowering drug prices in Medicare, AHA encouraged Congress to implement…
News
Drug companies raised prices faster than inflation for about half of all drugs covered by Medicare between July 2019 and July 2020, according to an analysis…
Headline
The administration yesterday issued an interim final rule requiring health plans to begin submitting annual information next year on prescription drug…
Headline
In addition to being based on a very small sample size, a recently published study on hospital costs for clinician-administered drugs under Medicare Part B…